So far, data from small-sized clinical trials and experimental approaches using murine DDAH transgenic and knock-out models have revealed controversial results regarding the impact of ADMA and its metabolizing enzyme DDAH in the development of hypertension. This evidence concerns the gene DDAH2 and Hypertension.